Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+.
about
SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathwaysNovel amphiphilic cationic porphyrin and its Ag(II) complex as potential anticancer agents.CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5.Differential localization and potency of manganese porphyrin superoxide dismutase-mimicking compounds in Saccharomyces cerevisiaeAn educational overview of the chemistry, biochemistry and therapeutic aspects of Mn porphyrins--From superoxide dismutation to H2O2-driven pathways.Radioprotection of the brain white matter by Mn(III) n-Butoxyethylpyridylporphyrin-based superoxide dismutase mimic MnTnBuOE-2-PyP5+.Anticancer therapeutic potential of Mn porphyrin/ascorbate systemRedox-modulated phenomena and radiation therapy: the central role of superoxide dismutases.Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP(5+).Mitochondrial metals as a potential therapeutic target in neurodegeneration.Simple biological systems for assessing the activity of superoxide dismutase mimics.Therapeutic potential of peroxynitrite decomposition catalysts: a patent review.Catalytic antioxidant therapy by metallodrugs: lessons from metallocorroles.Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier.Amphiphilic cationic Zn-porphyrins with high photodynamic antimicrobial activity.Manganese superoxide dismutase-mediated inside-out signaling in HaCaT human keratinocytes and SKH-1 mouse skin.Hypo-CpG methylation controls PTEN expression and cell apoptosis in irradiated lung.Radiation-mediated tumor growth inhibition is significantly enhanced with redox-active compounds that cycle with ascorbate.Challenges encountered during development of Mn porphyrin-based, potent redox-active drug and superoxide dismutase mimic, MnTnBuOE-2-PyP5+, and its alkoxyalkyl analogues.INK4a/ARF Expression Impairs Neurogenesis in the Brain of Irradiated Mice.Post-Irradiation Treatment with a Superoxide Dismutase Mimic, MnTnHex-2-PyP5+, Mitigates Radiation Injury in the Lungs of Non-Human Primates after Whole-Thorax Exposure to Ionizing Radiation.The manganese(III) porphyrin MnTnHex-2-PyP5+ modulates intracellular ROS and breast cancer cell migration: impact in doxorubicin-treated cells
P2860
Q28385000-54687638-1A51-402E-AFEF-87D07C0E2A3DQ30660258-D0B57237-D99D-41F6-9975-FA488D3AB81AQ33610242-5CD8B6B1-E69E-4B5D-B326-3F07C77EF96BQ34988449-3B41ADE2-5242-49D3-B204-1B523AEB8137Q35349280-1C5F9A64-B89D-423E-811F-4DA86D0DB692Q35428090-D7DF8D47-81AE-4270-A3D1-AA29F8030EF1Q36386390-B2BF4CF6-4961-488B-B15F-5A7FAD8B9190Q37617667-60407F10-3C96-4533-AFF6-A27C6C258AD3Q37629336-1B7446B0-F29C-426B-AFF3-4EDC129E0602Q37686294-8FF588CB-6AA3-4A14-B475-54E278ABCF39Q37734019-EB34EC81-50E0-4FD8-95D5-8CE44494F845Q38313367-BBF5F498-396F-4046-9448-61F87C985F93Q38348969-6785A417-9B35-4C2D-A746-AAD04231C5F3Q38768495-A579AE26-9590-466B-8EC0-69F4FB97B1CAQ39003712-2441C4F8-9156-4A4B-9F74-2B19BA801EC4Q39014809-9EF889A1-D6E0-499B-9BF4-64E78EE90858Q39638930-F5C017F8-C886-4157-90DE-AF41819149D0Q49484285-C2083AF7-DC75-4EC8-A7D8-CB83E9288038Q50927204-0F29D161-5162-46A5-9555-9AAB80B64647Q55002768-B72FC1D6-5BA4-4352-9278-042D755B7CDCQ55284502-88009602-AD60-4B2B-865F-4FD9A9903053Q58195104-FC8958C2-C9C6-4CB4-BB80-0812D028A15B
P2860
Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comprehensive pharmacokinetic ...... E-2-PyP5+ and MnTnHex-2-PyP5+.
@en
Comprehensive pharmacokinetic ...... E-2-PyP5+ and MnTnHex-2-PyP5+.
@nl
type
label
Comprehensive pharmacokinetic ...... E-2-PyP5+ and MnTnHex-2-PyP5+.
@en
Comprehensive pharmacokinetic ...... E-2-PyP5+ and MnTnHex-2-PyP5+.
@nl
prefLabel
Comprehensive pharmacokinetic ...... E-2-PyP5+ and MnTnHex-2-PyP5+.
@en
Comprehensive pharmacokinetic ...... E-2-PyP5+ and MnTnHex-2-PyP5+.
@nl
P2093
P2860
P50
P1476
Comprehensive pharmacokinetic ...... TE-2-PyP5+ and MnTnHex-2-PyP5+
@en
P2093
David S Warner
Huaxin Sheng
Ines Batinic-Haberle
Ivan Spasojevic
Zeljko Vujaskovic
P2860
P356
10.1016/J.FREERADBIOMED.2013.01.006
P577
2013-01-15T00:00:00Z